title: Postmarketing surveillance of new food ingredients: results from the program with the fat replacer olestra.
abstract: Market introduction of savory snacks containing olestra offered an opportunity to evaluate the safety of olestra in a free-living population and thereby compare the outcome to the previously established safety profile determined in clinical trials in which subjects were required to eat predetermined amounts at prescribed intervals. Therefore, a multifaceted postmarketing surveillance program was designed to evaluate consumer experience and safety of olestra in the marketplace. Customer comments were solicited through toll-free telephone numbers. Collected data were evaluated by both internal and external medical experts. About 10% of toll-free telephone calls reported health effects, most of which were gastrointestinal (GI) in nature. Clinical studies were designed and conducted to determine potential GI effects under the range of consumption patterns reported by toll-free calls. Health effects reported were those found commonly in the general population and analyses of the data found no biological reason to conclude that serious or meaningful health effects were the result of olestra consumption.
authors.affiliation: Food & Beverage Division, The Procter and Gamble Company, Cincinnati, OH 45224, USA.
authors.forename: G S
authors.initials: GS
authors.lastname: Allgood
authors.forename: D J
authors.initials: DJ
authors.lastname: Kuter
authors.forename: K T
authors.initials: KT
authors.lastname: Roll
authors.forename: S L
authors.initials: SL
authors.lastname: Taylor
authors.forename: N L
authors.initials: NL
authors.lastname: Zorich
mesh_terms: D000328:Adult; D000329:Advertising; D002986:Clinical Trials as Topic; D003256:Community Participation; D003625:Data Collection; D004064:Digestive System / Q000187:drug effects*; D019358:Fat Substitutes / Q000009:adverse effects*; D005227:Fatty Acids / Q000009:adverse effects*; D005503:Food Additives / Q000009:adverse effects*; D019649:Food Industry; D006801:Humans; D011358:Product Surveillance, Postmarketing; D011634:Public Health; D013395:Sucrose / Q000009:adverse effects* / Q000031:analogs & derivatives; D013689:Telephone; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D019358:Fat Substitutes; D005227:Fatty Acids; D005503:Food Additives; D013395:Sucrose; C013692:sucrose polyester